Dissecting cellulitis of the scalp treated by tumour necrosis factor inhibitors: a case series

Affiliation auteurs!!!! Error affiliation !!!!
TitreDissecting cellulitis of the scalp treated by tumour necrosis factor inhibitors: a case series
Type de publicationJournal Article
Year of Publication2021
AuteursFrechet L, Puzenat E, Charollais R, Dresco F, Carlet C, Gallais-Serezal I, Nardin C, Aubin F
JournalEUROPEAN JOURNAL OF DERMATOLOGY
Volume31
Pagination81-85
Date PublishedJAN
Type of ArticleArticle
ISSN1167-1122
Mots-clésAdalimumab, infliximab, issecting cellulitis of the scalp
Résumé

Background Dissecting cellulitis of the scalp (DCS), also known as Hoffmann disease or perifolliculitis capitis abscedens et suffodiens, is a rare disease characterized by chronic inflammation of the scalp. Treatment is difficult and often disappointing. Objectives To report our experience of TNF inhibitors in a series of patients with DCS. Materials & Methods We conducted a monocentric retrospective study of nine patients with DCS treated with TNF blocker after failure of other conventional treatments. Results After a mean duration of treatment by TNF inhibitors of 17 +/- 16 months, four patients (44% versus 0%) had a Physician's Global Assessment score of 0 or 1. We observed a 67% reduction in the number of inflammatory nodules, an 88% reduction in purulent drainage and a 45% improvement in Dermatology Life Quality Index. The mean treatment satisfaction index was 6.6 +/- 1.6 out of 10. Conclusion Our study suggests that TNF inhibitors are effective against disease activity and may improve quality of life in the management of DCS refractory to conventional treatments.

DOI10.1684/ejd.2021.3969